Drug Profile

Nefopam - Beijing CoSci Med Tech

Latest Information Update: 12 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Beijing CoSci Med-Tech
Class Antifibrotics; Non-opioid analgesics; Small molecules
Mechanism of Action Adrenergic receptor agonists; Muscarinic receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

12 Sep 2023 Discontinued - Preclinical for Pain in China (PO)
28 Aug 2020 No recent reports of development identified for preclinical development in Pain in China (PO, Controlled release)
28 Aug 2020 No recent reports of development identified for preclinical development in Pain in China (PO, Immediate release)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com